CANCER:

Non Small Cell Lung Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Lung Adenocarcinoma (508)

Lung Non-Squamous Non-Small Cell Cancer (108)

Lung Non-Small Cell Squamous Cancer (88)

Lung Adenocarcinoma (508)

Lung Non-Squamous Non-Small Cell Cancer (108)

Lung Non-Small Cell Squamous Cancer (88)

›

EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	erlotinib + capmatinib Sensitive: C4 – Case Studies Front Oncol - 4 days (New C4) erlotinib + capmatinib Sensitive : C4 Front Oncol - 4d	erlotinib + capmatinib Sensitive: C4 – Case Studies Front Oncol - 4 days erlotinib + capmatinib Sensitive : C4 Front Oncol - 4 days - (New C4)
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : B Onco Targets Ther - 6d	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : B Onco Targets Ther - 6 days - (New C3)
TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : B Onco Targets Ther - 6d	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : B Onco Targets Ther - 6 days - (New C3)
KRAS mutation + KMT2C mutation	Non Small Cell Lung Cancer	KRAS mutation + KMT2C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : C3 Onco Targets Ther - 6d	Immunotherapy Sensitive: C3 – Early Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : C3 Onco Targets Ther - 6 days - (New C3)
STRN-ALK fusion	Lung Adenocarcinoma	STRN-ALK fusion	Lung Adenocarcinoma	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 6 days (New C4) ensartinib Sensitive : C4 Curr Oncol - 6d	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 6 days ensartinib Sensitive : C4 Curr Oncol - 6 days - (New C4)
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week (New A1) toripalimab Sensitive : A1 GlobeNewswire - 1wk	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week toripalimab Sensitive : A1 GlobeNewswire - 1 week - (New A1)
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	selpercatinib Sensitive: A1 - Approval J Clin Oncol - 1 week (New C3) selpercatinib Sensitive : A1 J Clin Oncol - 1wk	selpercatinib Sensitive: A1 - Approval J Clin Oncol - 1 week selpercatinib Sensitive : A1 J Clin Oncol - 1 week - (New C3)
ALK translocation	Non Small Cell Lung Cancer	ALK translocation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria Lung Cancer - 1 week (New C3) crizotinib Sensitive : C2 Lung Cancer - 1wk	crizotinib Sensitive: C2 – Inclusion Criteria Lung Cancer - 1 week crizotinib Sensitive : C2 Lung Cancer - 1 week - (New C3)
EPHA5 mutation	Non Small Cell Lung Cancer	EPHA5 mutation	Non Small Cell Lung Cancer	atezolizumab Resistant: C3 – Early Trials BMC Pulm Med - 1 week (New C3) atezolizumab Resistant : C3 BMC Pulm Med - 1wk	atezolizumab Resistant: C3 – Early Trials BMC Pulm Med - 1 week atezolizumab Resistant : C3 BMC Pulm Med - 1 week - (New C3)
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials Curr Oncol - 1 week (New C4) lorlatinib Resistant : C3 Curr Oncol - 1wk	lorlatinib Resistant: C3 – Early Trials Curr Oncol - 1 week lorlatinib Resistant : C3 Curr Oncol - 1 week - (New C4)
CCDC85A-ALK fusion	Lung Adenocarcinoma	CCDC85A-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 1 week (New C4) alectinib Sensitive : C4 J Cell Mol Med - 1wk	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 1 week alectinib Sensitive : C4 J Cell Mol Med - 1 week - (New C4)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 2 weeks (New B) pembrolizumab Sensitive : A1 Lancet Oncol - 2wk	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 2 weeks pembrolizumab Sensitive : A1 Lancet Oncol - 2 weeks - (New B)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Front Oncol - 2 weeks (New C3) pembrolizumab Sensitive : A1 Front Oncol - 2wk	pembrolizumab Sensitive: A1 - Approval Front Oncol - 2 weeks pembrolizumab Sensitive : A1 Front Oncol - 2 weeks - (New C3)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval JTO Clin Res Rep - 2 weeks (New C3) crizotinib Sensitive : A1 JTO Clin Res Rep - 2wk	crizotinib Sensitive: A1 - Approval JTO Clin Res Rep - 2 weeks crizotinib Sensitive : A1 JTO Clin Res Rep - 2 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	savolitinib Sensitive: A1 - Approval Front Oncol - 2 weeks (New C4) savolitinib Sensitive : A1 Front Oncol - 2wk	savolitinib Sensitive: A1 - Approval Front Oncol - 2 weeks savolitinib Sensitive : A1 Front Oncol - 2 weeks - (New C4)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
ALK rearrangement + PD-L1 overepxression	Non Small Cell Lung Cancer	ALK rearrangement + PD-L1 overepxression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks (New C3) ALK inhibitor Resistant : C3 Front Immunol - 2wk	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks ALK inhibitor Resistant : C3 Front Immunol - 2 weeks - (New C3)
ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks (New C3) ALK inhibitor Resistant : C3 Front Immunol - 2wk	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks ALK inhibitor Resistant : C3 Front Immunol - 2 weeks - (New C3)
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks (New C4) pembrolizumab Sensitive : C4 Lung Cancer - 2wk	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks pembrolizumab Sensitive : C4 Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks (New C4) afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2wk	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2 weeks - (New C4)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A2 ESMO 2022 - 3wk	pembrolizumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks pembrolizumab Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : B ESMO 2022 - 3wk	Immunotherapy Sensitive: B - Late Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : B ESMO 2022 - 3 weeks - (New C3)
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Resistant : B ESMO 2022 - 3wk	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Resistant : B ESMO 2022 - 3 weeks - (New B)
HLA-A2 positive	Non Small Cell Lung Cancer	HLA-A2 positive	Non Small Cell Lung Cancer	OSE 2101 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) OSE 2101 Sensitive : B ESMO 2022 - 3wk	OSE 2101 Sensitive: B - Late Trials ESMO 2022 - 3 weeks OSE 2101 Sensitive : B ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : A1 ESMO 2022 - 3wk	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks afatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) lorlatinib Sensitive : A1 ESMO 2022 - 3wk	lorlatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks lorlatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks (New C3) gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3wk	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : A1 ESMO 2022 - 3wk	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks afatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) sotorasib Sensitive : A1 ESMO 2022 - 3wk	sotorasib Sensitive: A1 - Approval ESMO 2022 - 3 weeks sotorasib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) brigatinib Sensitive : A1 ESMO 2022 - 3wk	brigatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks brigatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) tepotinib Sensitive : A1 ESMO 2022 - 3wk	tepotinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks tepotinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) capmatinib Sensitive : A1 ESMO 2022 - 3wk	capmatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks capmatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pralsetinib Sensitive : A1 ESMO 2022 - 3wk	pralsetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks pralsetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks (New C3) gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3wk	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) mobocertinib Sensitive : A1 ESMO 2022 - 3wk	mobocertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks mobocertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) durvalumab Sensitive : A1 ESMO 2022 - 3wk	durvalumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks durvalumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) amivantamab-vmjw Sensitive : A1 ESMO 2022 - 3wk	amivantamab-vmjw Sensitive: A1 - Approval ESMO 2022 - 3 weeks amivantamab-vmjw Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : A2 ESMO 2022 - 3wk	alectinib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks alectinib Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New B) nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3 weeks - (New B)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) DZD9008 Sensitive : B ESMO 2022 - 3wk	DZD9008 Sensitive: B - Late Trials ESMO 2022 - 3 weeks DZD9008 Sensitive : B ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3wk	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3 weeks - (New B)
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label Onco Targets Ther - 3 weeks (New C4) capmatinib Sensitive : C1 Onco Targets Ther - 3wk	capmatinib Sensitive: C1 - Off-label Onco Targets Ther - 3 weeks capmatinib Sensitive : C1 Onco Targets Ther - 3 weeks - (New C4)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C1 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
HER-2 overexpression	Non Small Cell Lung Cancer	HER-2 overexpression	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : C2 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) anlotinib Sensitive : C2 ESMO 2022 - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks anlotinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C2 ESMO 2022 - 3wk	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks REGN5093 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C2 ESMO 2022 - 3wk	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks REGN5093 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials Anticancer Drugs - 3 weeks (New C4) ado-trastuzumab emtansine Sensitive : C3 Anticancer Drugs - 3wk	ado-trastuzumab emtansine Sensitive: C3 – Early Trials Anticancer Drugs - 3 weeks ado-trastuzumab emtansine Sensitive : C3 Anticancer Drugs - 3 weeks - (New C4)
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) brigatinib Sensitive : C3 ESMO 2022 - 3wk	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks brigatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) PD1 inhibitor Sensitive : C3 Cancers (Basel) - 3wk	PD1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks PD1 inhibitor Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) PD-L1 inhibitor Sensitive : C3 Cancers (Basel) - 3wk	PD-L1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks PD-L1 inhibitor Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) sintilimab Sensitive : C3 BMC Cancer - 3wk	sintilimab Sensitive: C3 – Early Trials BMC Cancer - 3 weeks sintilimab Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + tepotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) osimertinib + tepotinib Sensitive : C3 ESMO 2022 - 3wk	osimertinib + tepotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks osimertinib + tepotinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BPI-7711 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) BPI-7711 Sensitive : C3 ESMO 2022 - 3wk	BPI-7711 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks BPI-7711 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pralsetinib Sensitive : C3 ESMO 2022 - 3wk	pralsetinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pralsetinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib Sensitive : C3 ESMO 2022 - 3wk	capmatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3wk	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3wk	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	poziotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) poziotinib Sensitive : C3 ESMO 2022 - 3wk	poziotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks poziotinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KIT mutation	Non Small Cell Lung Cancer	KIT mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) CKD-702 Sensitive : C3 ESMO 2022 - 3wk	CKD-702 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks CKD-702 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) brigatinib Sensitive : C3 ESMO 2022 - 3wk	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks brigatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : C3 ESMO 2022 - 3wk	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks alectinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KRAS inhibitor Resistant : C3 ESMO 2022 - 3wk	KRAS inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks KRAS inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KRAS inhibitor Sensitive : C3 ESMO 2022 - 3wk	KRAS inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KRAS inhibitor Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RET positive + SMARCA4 mutation	Non Small Cell Lung Cancer	RET positive + SMARCA4 mutation	Non Small Cell Lung Cancer	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) RET inhibitor Resistant : C3 ESMO 2022 - 3wk	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks RET inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
RET positive + KRAS G12V	Non Small Cell Lung Cancer	RET positive + KRAS G12V	Non Small Cell Lung Cancer	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) RET inhibitor Resistant : C3 ESMO 2022 - 3wk	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks RET inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion + TP53 mutation	Non Small Cell Lung Cancer	EGFR exon 20 insertion + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET amplification + MET overexpression	Non Small Cell Lung Cancer	MET amplification + MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C3 ESMO 2022 - 3wk	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks REGN5093 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C3 ESMO 2022 - 3wk	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks REGN5093 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CLEC3B overexpression	Non Small Cell Lung Cancer	CLEC3B overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 18 mutation + EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation + EGFR exon 21 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) MEDI5752 Sensitive : C3 ESMO 2022 - 3wk	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks MEDI5752 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	crizotinib Resistant: C4 – Case Studies Exp Ther Med - 3 weeks (New C4) crizotinib Resistant : C4 Exp Ther Med - 3wk	crizotinib Resistant: C4 – Case Studies Exp Ther Med - 3 weeks crizotinib Resistant : C4 Exp Ther Med - 3 weeks - (New C4)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	lazertinib + ABN401 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) lazertinib + ABN401 Sensitive : D ESMO 2022 - 3wk	lazertinib + ABN401 Sensitive: D – Preclinical ESMO 2022 - 3 weeks lazertinib + ABN401 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) JIN-A02 Sensitive : D ESMO 2022 - 3wk	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks JIN-A02 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) JIN-A02 Sensitive : D ESMO 2022 - 3wk	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks JIN-A02 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	osimertinib Resistant: D – Preclinical ESMO 2022 - 3 weeks (New D) osimertinib Resistant : D ESMO 2022 - 3wk	osimertinib Resistant: D – Preclinical ESMO 2022 - 3 weeks osimertinib Resistant : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	erlotinib Resistant: D – Preclinical ESMO 2022 - 3 weeks (New D) erlotinib Resistant : D ESMO 2022 - 3wk	erlotinib Resistant: D – Preclinical ESMO 2022 - 3 weeks erlotinib Resistant : D ESMO 2022 - 3 weeks - (New D)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : C1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : C1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : C1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : C1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : C1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : C1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : C1	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : C1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : C1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : C1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	DP Sensitive: A1 - Approval DP Sensitive : A1	DP Sensitive: A1 - Approval DP Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1

Non Small Cell Lung Cancer

Associations(2886)

Associations
(2886)